HCV prevalence in Asia and the Pacific varies between countries. HCV infection is due to unsterile medical injections (2 , 3) contaminated blood transfusions, (4) traditional cultural practices60 and, more recently, injecting drug use. (5) While iatrogenic transmission still occurs in some countries, transmission as the result of injecting drug use is increasing. (6)
We believe that all services both prevention & treatment for all people who use drugs, irrespective of age or gender, must be acceptable, accessible, compassionate, comprehensive, evidence-based and voluntary.
[EXTENDED DEADLINE till 27th January 2017]
ANPUD is hiring a project coordinator to manage its new project - Strengthening HIV and Harm Reduction Responses for PWID in Asia. The goal of the regional project is to “increase access to essential HIV and harm reduction services for people who inject drugs in Asia through removing legal barriers, community systems strengthening and increasing the evidence base”.
This is the first-ever global report on treatment access to hepatitis C medicines. The report provides the information that countries and health authorities need to identify the appropriate HCV treatment, and procure it at affordable prices. The report uses the experience of several pioneering countries to demonstrate how barriers to treatment access can be overcome.
Bangkok, Thailand (18th October, 2016) - As ASEAN Ministers meet in Singapore this week at the 5th ASEAN Ministerial Meeting on Drug Matters to agree a new regional 10-year plan on drugs, civil society groups highlight the urgent need for governments to promote and protect the right to life.
In this submission, the HRDP, ANPUD and INPUD map out key tensions between the Philippine's current national drug strategy, including the widespread extrajudicial killings of people suspected of using and dealing drugs and the full and effective realisation of economic, social and cultural rights.